AstraZeneca plc (LON:AZN) had its target price upped by research analysts at Jefferies Group LLC from GBX 4,900 ($64.66) to GBX 5,100 ($67.30) in a research report issued on Monday, October 16th. The firm currently has a “hold” rating on the biopharmaceutical company’s stock. Jefferies Group LLC’s price target points to a potential upside of 0.99% from the company’s previous close.
Several other analysts have also issued reports on the stock. Deutsche Bank AG reaffirmed a “buy” rating and set a GBX 5,600 ($73.90) target price on shares of AstraZeneca plc in a report on Wednesday, October 11th. UBS Group AG set a GBX 4,550 ($60.04) target price on shares of AstraZeneca plc and gave the stock a “neutral” rating in a report on Monday, October 9th. Shore Capital reaffirmed a “hold” rating on shares of AstraZeneca plc in a report on Monday, October 9th. HSBC Holdings plc upped their target price on shares of AstraZeneca plc from GBX 4,100 ($54.10) to GBX 4,150 ($54.76) and gave the stock a “reduce” rating in a report on Monday, October 9th. Finally, Barclays PLC reaffirmed an “overweight” rating and set a GBX 6,300 ($83.14) target price on shares of AstraZeneca plc in a report on Thursday, October 5th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of GBX 5,172.64 ($68.26).
Shares of AstraZeneca plc (LON AZN) opened at 5050.00 on Monday. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00. The company’s 50 day moving average price is GBX 4,979.07 and its 200 day moving average price is GBX 4,921.00. The stock’s market capitalization is GBX 63.93 billion.
ILLEGAL ACTIVITY WARNING: This report was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2017/10/27/astrazeneca-plc-azn-pt-raised-to-gbx-5100-at-jefferies-group-llc.html.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.